Full-Time

Rare Disease Account Manager

Posted on 5/9/2026

 Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharmaceutical company developing medicines

Compensation Overview

$132k - $205.4k/yr

+ Incentive Opportunity

Charlotte, NC, USA

In Person

Must reside within 50 miles of the Charlotte primary city in the sales territory.

Category
Sales & Account Management (1)
Required Skills
Sales
Requirements
  • Bachelor’s degree
Responsibilities
  • The Rare Disease Account Manager will work with the Area Business Lead, Rare Disease to develop a territory-specific business/account plan to include strategies and tactics aimed at increasing disease-state awareness, implementing diagnostic approaches, identifying and pursuing business opportunities and meeting sales goals in a rare disease space.
  • Communicates and collaborates within a cross functional team (i.e. other RDAMs, brand marketing, market access, medical affairs and thought leader liaisons) necessary to meet business objectives.
  • Develops in-depth knowledge of current and future competition and executes sales strategies to effectively compete and achieve patient acquisition and revenue goals.
  • The RDAM will build and maintain proficiency in relevant disease states, patient and clinic experience, market landscape and product knowledge.
  • Effectively utilize all available tools, technology and resources to analyze and identify market opportunities trends.
  • Proven ability to navigate and identify opportunities through dynamic healthcare landscape including academic institutions, IDNs, community practices, and local patient advocacy groups
  • Ability to successfully execute upon a rare disease selling model.
  • Sponsor and display at relevant congresses and society meetings.
  • Demonstrated expertise with longer selling cycle and complex patient journey across portfolio of products.
  • Territory Analysis / Business Planning: Uses competitive data and business reports to track progress and uncover opportunities, including sales data and promotional budget; Displays knowledge of territory and business conditions that impact sales results to establish near term priorities for his/her territory business plan; Responds compliantly to competitive threats and opportunities; Educates office staff on payer guidelines and reimbursement procedures to increase pull through; Effectively utilizes promotional materials
  • Selling Skills, Engagement & Account Pull Through: Maintains ongoing awareness of internal support team resources available throughout the ecosystem and utilizes appropriately; Applies market and industry knowledge to overcome objections and influence prescribing habits during the total office call; Identifies territory professional groups to network and ensure access/exposure to potential key opinion leaders; Builds strong relationships with all key office/practice personnel and focuses on patient health in conversations with all staff members; Takes personal responsibility for follow-through and providing value to the accounts by providing accurate information in response to their needs; Delivers effective and balanced office calls and sales presentations utilizing the appropriate approved marketing materials and technical references (e.g. studies, package inserts, etc.) with clarity and confidence to help HCPs enhance patient outcomes; demonstrates competent product knowledge of own product and competition
Desired Qualifications
  • MBA or other related graduate degree
  • 3+ years sales experience in rare disease, immunology, renal, oncology, and/or hospital account manager is strongly preferred
  • Proven track record for consistently meeting or exceeding financial and/or other quantitative targets, as well as qualitative goals in a fast-paced dynamic sales environment
  • Candidate must display intellectual curiosity, business acumen, perseverance, relationship mastery, collaboration, passion for the patient
  • Ability to interpret, analyze and leverage data to identify trends, gain insights, drive pull through, and lead live engagements with customers in the local business environment
  • Demonstrates strategic thinking to create a customer/account engagement plan, taking a dynamic and collaborative approach to maximize the business
  • Exhibits intellectual curiosity and maintains ongoing awareness of trends in his/her area of expertise and leverages knowledge and insights to positively impact the business
  • Respectfully collaborates to cultivate partnerships with a variety of internal and external stakeholders and incorporates these diverse views into decision making process within a complex and competitive healthcare environment (e.g., payers, health systems, matrix partners)
  • Apply expert knowledge of the marketplace, applicable competitors, industry, and matrix functional activities/plans to anticipate and optimally manage business opportunities and challenges in an ambiguous environment
  • Demonstrates a commitment to ethical business practices, an understanding of regulatory standards, and the ability to execute business activities in compliance with Company policies and guidance.
  • Facilitates clinical dialogue that compels the customer to act on behalf of their patients and engage the entire account to understand any obstacles that exist to provide appropriate solutions to ensure customer needs are met
  • Develop and position Otsuka as a leader with key Nephrology stakeholders and other specialty customers and targeted accounts (large group practices and community practices)
 Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical is a global health-focused company that develops and markets medicines and nutraceutical products. It creates pharmaceuticals like Abilify (aripiprazole), an antipsychotic, and consumer health brands such as Pocari Sweat, an ion-replacement drink. Its products work by medical mechanisms (Abilify modulates dopamine and serotonin receptors to treat psychiatric conditions) and by supporting hydration and electrolyte balance (Pocari Sweat). Otsuka differentiates itself through a long, international growth path from its roots as a Japanese chemical manufacturer, a balanced portfolio spanning prescription drugs and health beverages, and a philosophy of developing new products to improve health worldwide. Its goal is to deliver healthier outcomes for people around the world by expanding access to innovative medicines and health-related consumer products.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Simplify Jobs

Simplify's Take

What believers are saying

  • Voyxact achieves 82.5% hematuria improvement in IgAN trial at 48 weeks.
  • Acquired Transcend Therapeutics for $700M to advance psychiatric MDMA analog.
  • Partnered Keio University on May 8, 2025, for psychedelics infrastructure.

What critics are saying

  • AbbVie acquires Gilgamesh bretisilocin for $1.2B, leapfrogging Otsuka psychedelics.
  • Voyxact confirmatory trial fails kidney preservation in 18-24 months.
  • Japanese regulations block psychedelics trials in 24-36 months.

What makes Otsuka Pharmaceutical unique

  • Pioneered IV solutions in 1946, becoming Japan's top supplier.
  • Launched Pocari Sweat ion drink and Abilify antipsychotic globally.
  • Focuses on carbostyril-based original drugs since 1980.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Otsuka Pharmaceutical who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

The Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.

Business Wire
Mar 2nd, 2026
Paradise ultrasound renal denervation system now covered by insurance in Japan for resistant hypertension

Otsuka Medical Devices and Otsuka Pharmaceutical have launched the Paradise Ultrasound Renal Denervation system in Japan, with National Health Insurance coverage effective 1 March. The device, developed by US subsidiary Recor Medical, treats resistant hypertension by reducing sympathetic nerve overactivity surrounding renal arteries. The system targets patients whose blood pressure remains above target despite using three different antihypertensive medications, including a diuretic. This marks Japan's first ultrasound renal denervation treatment. The Paradise system received FDA approval in the US in November 2023. Under a co-promotion agreement, both Otsuka companies will leverage their cardiovascular and renal expertise to deliver the treatment according to guidelines established by Japanese medical societies. The system offers a new option for resistant hypertension patients at high risk of serious cardiovascular complications.

The Associated Press
Feb 6th, 2026
Sky Labs secures exclusive deal with Otsuka Pharmaceutical to launch ring-type blood pressure monitor in Japan

Sky Labs has signed an exclusive distribution agreement with Otsuka Pharmaceutical to launch its ring-type blood pressure monitor, CART BP pro, in Japan's hospital and clinic market. The deal follows an MoU signed in December 2024. CART BP pro uses photoplethysmography technology to measure blood pressure without a cuff, allowing comfortable monitoring during daily activities and sleep. The device has already achieved success in South Korea, with over 150,000 prescriptions across 1,700 medical institutions since its 2023 approval and national health insurance coverage in 2024. Japan's hypertension market includes approximately 43 million patients, with 29% failing to achieve blood pressure control and 33% unaware of their condition. Sky Labs will leverage Otsuka's distribution network and cardiovascular expertise to expand across Japanese healthcare facilities.